Home Markets Earnings Estimate Forecast on Alkermes PLC(ALKS)

Earnings Estimate Forecast on Alkermes PLC(ALKS)


Alkermes PLC(ALKS): For the most recent quarter end, Alkermes PLC reported Annual Earnings of $-0.04. Based on the filings, last years Annual Earnings was, $-0.92. For the most recent quarter end, ALKS reported a surprise Earnings per Share of 78.95% . The consensus estimate for current quarter is $-0.19 and for the current fiscal year, the estimate is $-0.59. For the Next fiscal year, the estimate is $0.12 based on the consensus. Dublin 4 based Alkermes PLC Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Apr 27, 2017.

Alkermes PLC has received $-0.19 as the consensus Earnings Estimate for the Quarter ending on Mar 2017 ,According to the estimate provided by 1 Financial Advisor in the Stock Trading Firms. The EPS growth rate is projected at 40.63%. Alkermes PLC reported better than expected with a surprise EPS of 78.95% or $0.15 during its most recent quarterly earnings. The Actual EPS was $-0.04 compared to the Estimated EPS of $-0.19. According to the corporate earnings calendar, Alkermes PLC will release next earnings on Apr 27, 2017 with an estimated EPS consensus of $-0.19. Based on the consensus of stock financial advisors the stock has a price target of $69.2. Current year estimate on EPS consensus is $-0.59.

For Dividend Investing Stock Market Traders Alkermes PLC has a Dividend Yield of 0% with an Annual Dividend of $0.

Alkermes Plc Last issued its quarterly earnings results on Feb 15, 2017. The company reported $0.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.10. Analyst had a consensus of $0.05. The company had revenue of $213.51 million for the quarter, compared to analysts expectations of $206.38 million. The companys revenue was up 30.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.14 EPS.

Company has reported several Insider transactions to the SEC, on Feb 16, 2017, Elliot Ehrich (EVP, R&D & CMO, Alkermes, Inc.) sold 11,000 shares at 57.02 per share price.On Feb 2, 2017, Paul J Mitchell (director) sold 1,500 shares at 54.45 per share price.On Jan 10, 2017, Shane Cooke (President, Alkermes plc) sold 550 shares at 60.27 per share price.

Alkermes plc (NASDAQ:ALKS) witnessed a decline in the market cap on Wednesday as its shares dropped 1.66% or 0.9 points. After the session commenced at $54.01, the stock reached the higher end at $54.345 while it hit a low of $53.14. With the volume soaring to 772,404 shares, the last trade was called at $53.29. The company has a 52-week high of $60.74. The company has a market cap of $8,129 million and there are 152,547,460 shares in outstanding. The 52-week low of the share price is $27.14.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.



Please enter your comment!
Please enter your name here